CC-38
Late-stage Prostate Cancer and Colorectal Cancer
Pre-clinical / Phase 1 (Initiating)Active
Key Facts
Indication
Late-stage Prostate Cancer and Colorectal Cancer
Phase
Pre-clinical / Phase 1 (Initiating)
Status
Active
Company
About Curacell
Curacell is a private, clinical-stage biotech developing next-generation T-cell therapies for solid tumors. Its proprietary CytoPLY™ platform is designed to enhance the cytotoxicity, breadth, and expansion speed of T-cell products like TILs and TCR-Ts, aiming to treat 'cold' tumors with high unmet need. The company is initiating its first clinical program with its lead candidate, CC-38, for prostate and colorectal cancer, building on promising results from early patient-named treatments. Curacell leverages a management team and advisory board with strong European academic and clinical expertise in oncology and cell therapy.
View full company profile